Stabilization of a β-hairpin in monomeric Alzheimer's amyloid-β peptide inhibits amyloid formation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 13, 2008, Pages 5099-5104

  Hoyer, Wolfgang ^a   Grönwall, Caroline ^b   Jonsson, Andreas ^b,c   Ståhl, Stefan ^b   Härd, Torleif ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^c Affibody AB   (Sweden)

Author keywords

A peptide; Engineered binding protein; Molecular recognition; Nuclear magnetic resonance; Protein structure

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; DISULFIDE; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ARTICLE; BETA CHAIN; BINDING AFFINITY; CONFORMATIONAL TRANSITION; MOLECULAR RECOGNITION; NONHUMAN; OLIGOMERIZATION; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; PROTEIN STRUCTURE; STOICHIOMETRY; AMINO ACID SEQUENCE; CHEMICAL STRUCTURE; CHEMISTRY; DIMERIZATION; HYDROPHOBICITY; METABOLISM; MOLECULAR GENETICS; PROTEIN BINDING; PROTEIN QUATERNARY STRUCTURE; SEQUENCE ALIGNMENT; TITRIMETRY;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN; DIMERIZATION; DISULFIDES; HYDROPHOBICITY; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, SECONDARY; SEQUENCE ALIGNMENT; TITRIMETRY;

EID: 42449111198     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0711731105     Document Type: Article

References (41)

1. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297:353-356.
2. Lansbury PT, Lashuel HA (2006) A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443:774-779.
3. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol 8:101-112.
4. Kayed R, et al. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486-489.
5. Lambert MP, et al. (1998) Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448-6453.
6. Walsh DM, et al. (2002) Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535-539.
7. Walsh DM, Selkoe DJ (2007) Aβ Oligomers - a decade of discovery. J Neurochem 101:1172-1184.
8. Citron M (2004) Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 5:677-685.
9. Masliah E, et al. (2005) Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64:129-131.
10. Schenk D, et al. (1999) Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173-177.
11. Weiner HL, Frenkel D (2006) Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol 6:404-416.
12. Frenkel D, Balass M, Katchalski-Katzir E, Solomon B (1999) High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-amyloid peptide is essential for modulation of fibrillar aggregation. J Neuroimmunol 95:136-142.
13. Solomon B, Koppel R, Frankel D, Hanan-Aharon E (1997) Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc Natl Acad Sci USA 94:4109-4112.
14. DeMattos RB, et al. (2001) Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brainAβ burden in amousemodel of Alzheimer's disease. Proc Natl Acad Sci USA 98:8850-8855.
15. Sciarretta KL, Gordon DJ, Meredith SC (2006) Peptide-based inhibitors of amyloid assembly. Methods Enzymol 413:273-312.
16. Soto C, et al. (1998) β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med 4:822-826.
17. Tjernberg LO, et al. (1996) Arrest of β-amyloid fibril formation by a pentapeptide ligand. J Biol Chem 271:8545-8548.
18. Gardberg AS, et al. (2007) Molecular basis for passive immunotherapy of Alzheimer's disease. Proc Natl Acad Sci USA 104:15659-15664.
19. Matsuoka Y, et al. (2003) Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to β-amyloid. J Neurosci 23:29-33.
20. Grönwall C, et al. (2007) Selection and characterization of affibody ligands binding to Alzheimer amyloid β peptides. J Biotechnol 128:162-183.
21. Binz HK, Amstutz P, Plückthun A (2005) Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 23:1257-1268.
22. Nord K, et al. (1997) Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain. Nat Biotechnol 15:772-777.
23. Tolmachev V, et al. (2007) Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res 67:2773-2782.
24. Deisenhofer J (1981) Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-Å resolution. Biochemistry 20:2361-2370.
25. Lendel C, Dogan J, Härd T (2006) Structural basis for molecular recognition in an affibody:affibody complex. J Mol Biol 359:1293-1304.
26. Wahlberg E, et al. (2003) An affibody in complex with a target protein: structure and coupled folding. Proc Natl Acad Sci USA 100:3185-3190.
27. Petkova AT, et al. (2005) Self-propagating, molecular-level polymorphism in Alzheimer's β-amyloid fibrils. Science 307:262-265.
28. Petkova AT, Yau WM, Tycko R (2006) Experimental constraints on quaternary structure in Alzheimer's β-amyloid fibrils. Biochemistry 45:498-512.
29. Smith TJ, Stains CI, Meyer SC, Ghosh I (2006) Inhibition of β-amyloid fibrillization by directed evolution of a β-sheet presenting miniature protein. J Am Chem Soc 128:14456-14457.
30. Lührs T, et al. (2005) 3D structure of Alzheimer's amyloid-β(1-42) fibrils. Proc Natl Acad Sci USA 102:17342-17347.
31. Olofsson A, Sauer-Eriksson AE, Öhman A (2006) The solvent protection of Alzheimer amyloid-β-(1-42) fibrils as determined by solution NMR spectroscopy. J Biol Chem 281:477-483.
32. Wetzel R, Shivaprasad S, Williams AD (2007) Plasticity of amyloid fibrils. Biochemistry 46:1-10.
33. Hou L, et al. (2004) Solution NMR studies of the Aβ(1-40) and Aβ(1-42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation. J Am Chem Soc 126:1992-2005.
34. Bucciantini M, et al. (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416:507-511.
35. Habicht G, et al. (2007) Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils. Proc Natl Acad Sci USA 104:19232-19237.
36. Lashuel HA, Lansbury PT, Jr (2006) Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q Rev Biophys 39:167-201.
37. Stuart AC, Borzilleri KA, Withka JM, Palmer AG (1999) Compensating for variations in 1H-13C scalar coupling constants in isotope-filtered NMR experiments. J Am Chem Soc 121:5346-5347.
38. Cornilescu G, Delaglio F, Bax A (1999) Protein backbone angle restraints from searching a database for chemical shift and sequence homology. J Biomol NMR 13:289-302.
39. Schwieters CD, Kuszewski JJ, Tjandra N, Clore GM (2003) The Xplor-NIH NMR molecular structure determination package. J Magn Reson 160:65-73.
40. Kuszewski J, Gronenborn AM, Clore GM (1999) Improving the packing and accuracy of NMR structures with a pseudopotential for the radius of gyration. J Am Chem Soc 121:2337-2338.
41. Kuszewski J, Gronenborn AM, Clore GM (1997) Improvements and extensions in the conformational database potential for the refinement of NMR and X-ray structures of proteins and nucleic acids. J Magn Reson 125:171-177.